ijms-logo

Journal Browser

Journal Browser

Pathogenesis and Molecular Treatment of Primary Liver Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 July 2025 | Viewed by 1471

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy
Interests: liver cancer; hepatocellular carcinoma; cholangiocarcinoma; hepatoblastoma; molecular pathogenesis; targeted therapies

Special Issue Information

Dear Colleagues,

Primary liver cancer (PLC) is a group of tumor entities that are characterized by their high aggressiveness and dismal outcomes. PLC has steadily increased in incidence in recent decades and has become a significant health concern worldwide. Histologically, PLC mainly consists of hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) in adulthood, and hepatoblastoma (HBL) in childhood. Due to its asymptomatic nature in the early phases of the disease, PLC is generally diagnosed when the tumor is inoperable, and systemic treatments have limited efficacy. Therefore, a better understanding of the molecular pathogenesis of PLC is imperative to improve patients’ outcomes. In recent years, numerous signaling cascades involved in PLC development and progression have been elucidated, and several molecularly and immunologically based therapies have been generated, with some becoming the first-line treatment for specific tumor subsets.

Given PLC’s importance in the medical and research fields, the International Journal of Molecular Sciences is launching this Special Issue.

Specifically, we aim to showcase the current knowledge on the molecular pathogenesis of PLC and the efforts on anticancer drug development. Original research articles, review articles, and short communications within the described research topic are welcome.

Dr. Diego F. Calvisi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • primary liver cancer
  • cholangiocarcinoma
  • hepatocellular carcinoma
  • hepatoblastoma
  • molecular pathogenesis
  • targeted therapies
  • anticancer drug

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 9292 KiB  
Article
The Cell Polarity Protein MPP5/PALS1 Controls the Subcellular Localization of the Oncogenes YAP and TAZ in Liver Cancer
by Marcell Tóth, Shan Wan, Jennifer Schmitt, Patrizia Birner, Teng Wei, Fabian von Bubnoff, Carolina de la Torre, Stefan Thomann, Federico Pinna, Peter Schirmacher, Sofia Maria Elisabeth Weiler and Kai Breuhahn
Int. J. Mol. Sci. 2025, 26(2), 660; https://doi.org/10.3390/ijms26020660 - 14 Jan 2025
Cited by 1 | Viewed by 1030
Abstract
The oncogenes yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are potent liver oncogenes. Because gene mutations cannot fully explain their nuclear enrichment, we aim to understand which mechanisms cause YAP/TAZ activation in liver cancer cells. The [...] Read more.
The oncogenes yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are potent liver oncogenes. Because gene mutations cannot fully explain their nuclear enrichment, we aim to understand which mechanisms cause YAP/TAZ activation in liver cancer cells. The combination of proteomics and functional screening identified numerous apical cell polarity complex proteins interacting with YAP and TAZ. Co-immunoprecipitation (Co-IP) experiments confirmed that membrane protein palmitoylated 5 (MPP5; synonym: PALS1) physically interacts with YAP and TAZ. After removing different MPP5 protein domains, Co-IP analyses revealed that the PDZ domain plays a crucial role in YAP binding. The interaction between YAP and MPP5 in the cytoplasm of cancer cells was demonstrated by proximity ligation assays (PLAs). In human hepatocellular carcinoma (HCC) tissues, a reduction in apical MPP5 expression was observed, correlating with the nuclear accumulation of YAP and TAZ. Expression data analysis illustrated that MPP5 is inversely associated with YAP/TAZ target gene signatures in human HCCs. Low MPP5 levels define an HCC patient group with a poor clinical outcome. In summary, MPP5 facilitates the nuclear exclusion of YAP and TAZ in liver cancer. This qualifies MPP5 as a potential tumor-suppressor gene and explains how changes in cell polarity can foster tumorigenesis. Full article
(This article belongs to the Special Issue Pathogenesis and Molecular Treatment of Primary Liver Cancer)
Show Figures

Figure 1

Back to TopTop